Business context and reporting period
The supplied filing is Leap Therapeutics, Inc.’s Form 10-Q for the quarter ended March 31, 2017, not a filing for Cypherpunk Technologies Inc. Investors should verify the issuer before relying on this summary. Leap is a clinical-stage biopharmaceutical company developing the cancer candidates DKN-01 and TRX518. It reported no product revenue and no approved products.
In January 2017, Leap merged with Macrocure, completed a reverse stock split, converted its preferred stock and related-party debt into common stock, and began Nasdaq trading as LPTX. The financial statements are unaudited; amounts below are in USD millions unless otherwise noted.
Financial performance and position
| Metric | Q1 2017 | Q1 2016 |
|---|---|---|
| Revenue | None | None reported |
| Research and development expense | $6.404 | $4.087 |
| General and administrative expense | $3.804 | $1.056 |
| Total operating expenses / operating loss | $10.208 | $5.143 |
| Net loss | $9.414 | $5.147 |
| Net loss attributable to common stockholders | $9.658; $1.39 per share | Not presented; no common shares outstanding |
| Operating cash used | $6.349 | $4.133 |
| Investing cash used | $0.065 | $0.030 |
| Financing cash provided | $29.848 | $6.900 |
Operating expenses rose $5.065 million year over year. R&D expense increased $2.317 million, including higher stock-based compensation and clinical research costs; G&A increased $2.748 million, principally from stock-based compensation and public-company, legal, audit and consulting costs. Q1 2017 included $3.623 million of stock-based compensation, versus $0.009 million in Q1 2016. Other income included $0.397 million of Australian R&D incentives and $0.468 million of foreign-currency gains; interest expense was $0.121 million.
At March 31, 2017, cash and cash equivalents were $23.800 million, total current assets $27.286 million, current liabilities $4.612 million, and total assets $28.779 million. Stockholders’ equity was $24.167 million and accumulated deficit $110.084 million. Related-party notes and accrued interest of $31.145 million were converted into common stock in January; no notes payable remained on the quarter-end balance sheet. The filing does not provide a clear operating margin measure; the company had no revenue and an operating loss.
Material changes, outlook and risks
- Cash increased from $0.793 million at December 31, 2016, mainly due to merger-related proceeds and a $10 million private stock investment. Financing cash flow also included $21.165 million from the Macrocure transaction; these proceeds should not be confused with recurring operating cash generation.
- Management expected March 31 cash plus approximately $3.2 million in Australian R&D incentive receipts to fund operations for at least 12 months from issuance; MD&A specified funding through at least May 12, 2018. The company expects continued losses and rising expenses, and may need additional financing or collaboration funding. Failure to secure funds could force delays, reductions or cancellations of trials and research programs.
- Clinical updates included preliminary median progression-free survival of 9.4 months in a DKN-01 biliary tract cancer trial, expansion of a TRX518 monotherapy study, and reported biomarker findings. These are early, investigational results; neither candidate had FDA approval, and results do not assure approval or commercial success.
- Manufacturing commitments for the candidates totaled $5.738 million. The company also granted a perpetual royalty interest to a shareholder vehicle: 5% of net sales of TRX518 products and 2% of net sales of DKN-01 products, if any.
- Ten entities, including major pharmaceutical companies, opposed a European patent covering TRX518 in combination with chemotherapy; Leap said it would defend the patent. Separate opposition and appeal proceedings also concerned TRX518 patent claims. Patent outcomes could affect the company’s intellectual-property position.
- The filing identifies clinical, regulatory, financing, manufacturing, competition and intellectual-property uncertainties. Management reported disclosure controls effective as of March 31, 2017 and no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Confirm the filing belongs to Leap Therapeutics, Inc.; the request metadata names a different company.
- Check actual receipt and timing of the anticipated Australian R&D incentive payments and compare cash runway with subsequent operating burn.
- Review the full clinical-trial data and status behind the preliminary 9.4-month progression-free-survival figure and other reported activity.
- Assess the effect of the perpetual product royalty, manufacturing commitments and stock-based compensation on future economics and dilution.
- Track the TRX518 patent opposition and appeal proceedings, and any resulting changes to patent protection.